Larkspur Biosciences

Larkspur Biosciences is developing new precision immunotherapies to conquer cancer. Larkspur's approach targets the unique ways in which tumors hijack the immune system, overcoming these bottlenecks by developing precise immunotherapies for molecularly defined patient populations. The company is advancing its first-in-class programs to defeat tumors and achieve strong and sustained immune responses in colorectal cancer (CRC) and other cancers. LarkX, the company’s discovery platform, leverages tumor genetics and immune phenotypes from patient data to drive its pipeline and provide opportunities to address multiple types of cancer.